8-K/AExhibits & Filings

AbbVie Inc. 8-K/A Report, Exhibit Filing (Aug 7, 2015)

Filed August 7, 2015For Securities:ABBV

Summary

This Form 8-K/A filing from AbbVie Inc. serves as an amendment to a previous report, primarily to include essential financial information regarding its acquisition of Pharmacyclics, Inc. The amendment confirms the completion of the Pharmacyclics acquisition on May 26, 2015, and crucially, provides investors with the audited financial statements of Pharmacyclics for the periods ending December 31, 2014 and 2013, along with unaudited interim financial data as of March 31, 2015. It also includes pro forma combined financial statements of earnings for AbbVie, reflecting the impact of the acquisition on a combined basis for the year ended December 31, 2014, and the six months ended June 30, 2015. For investors, this filing is significant as it retroactively supplies the detailed financial picture of the acquired entity, Pharmacyclics, and presents a forward-looking view of the combined company's financial performance through pro forma statements. This allows for a more comprehensive understanding of the financial implications and potential synergies arising from the integration of Pharmacyclics into AbbVie's operations, particularly concerning its drug portfolio and market position.

Key Highlights

  • 1AbbVie Inc. officially amends its prior Form 8-K filing to include detailed financial statements of the acquired entity, Pharmacyclics, Inc.
  • 2The acquisition of Pharmacyclics, Inc. was completed on May 26, 2015, pursuant to the Merger Agreement.
  • 3Key financial information for Pharmacyclics, including audited statements for FY 2014 and 2013 and unaudited statements for Q1 2015, is now incorporated by reference and filed.
  • 4The filing includes pro forma condensed combined statements of earnings for AbbVie, showing the projected financial impact of the Pharmacyclics acquisition.
  • 5Pro forma financial data is provided for the full year 2014 and the first six months of 2015, enabling investors to assess the combined entity's performance.
  • 6This amendment ensures investors have access to the necessary financial data for a complete understanding of the Pharmacyclics acquisition's financial implications.
  • 7William J. Chase, AbbVie's Executive Vice President and Chief Financial Officer, signed the report, indicating the CFO's attestation to the provided information.

Frequently Asked Questions

This Form 8-K/A filing is an amendment to a previous report. Its main purpose is to formally include the financial statements and pro forma financial information related to AbbVie's acquisition of Pharmacyclics, Inc., which was completed on May 26, 2015.

The filing incorporates by reference Pharmacyclics' audited consolidated financial statements for the years ended December 31, 2014 and 2013, and its unaudited condensed consolidated balance sheets and statements of operations as of March 31, 2015, and for the three-month periods ended March 31, 2015 and 2014. This allows investors to review the historical financial performance and position of the acquired company.

Pro forma financial information presents hypothetical combined financial statements of earnings for AbbVie, reflecting the acquisition of Pharmacyclics as if it had occurred at an earlier point in time. This helps investors understand the potential financial impact and combined performance of the two companies post-acquisition, based on historical data for the year ended December 31, 2014, and the six months ended June 30, 2015.

The acquisition of Pharmacyclics, Inc. by AbbVie Inc. was completed on May 26, 2015.